Pacira's long-acting non-opioidpain drug gets FDA ok
This article was originally published in Scrip
Executive Summary
The US FDA has cleared for marketing Pacira Pharmaceuticals' long-acting version of bupivacaine, Exparel (bupivacaine extended-release liposome injection), as a postsurgical analgesic. Although the stock hit a high of $11.10 as investors awaited word on FDA approval, the company must still spend considerable time and resources to gain acceptance of the product by hospitals, which have relied on conventionally released bupivacaine. Pacira's shares closed down 4% to $9.78 on 31 October.
You may also be interested in...
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
The latest drug development news and highlights from our US FDA Performance Tracker.
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.